Inhibitor Therapeutics, Inc.
INTI
$0.09
$0.0117.03%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 395.00K | 355.10K | 557.90K | 363.40K | 370.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 618.60K | 695.60K | 1.32M | 741.20K | 695.80K |
| Operating Income | -618.60K | -695.60K | -1.32M | -741.20K | -695.80K |
| Income Before Tax | -613.90K | -686.40K | -1.30M | -712.20K | -659.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -613.90K | -686.40K | -1.30M | -712.20K | -659.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -613.90K | -686.40K | -1.30M | -712.20K | -659.90K |
| EBIT | -618.60K | -695.60K | -1.32M | -741.20K | -695.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 173.31M | 172.57M | 172.57M | 172.57M | 172.57M |
| Average Diluted Shares Outstanding | 173.31M | 172.57M | 172.57M | 172.57M | 172.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |